secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009898
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus expects ~$514M cash at year-end 2025; CEO to present at JPM conference
-------------------------------------------------------------------------------

- Preliminary unaudited cash, cash equivalents, and short-term investments of ~$514M as of Dec 31, 2025.
- Actual results may differ materially due to completion of financial closing procedures.
- CEO Marino Garcia to present at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.
- Presentation focuses on advancing the autoimmune-focused pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/0001193125-26-009898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer